Board of Scientific Counselors, National Center for Injury Prevention and Control: Notice of Charter Renewal, 71807-71808 [2015-29257]
Download as PDF
<![CDATA[
71807
Federal Register / Vol. 80, No. 221 / Tuesday, November 17, 2015 / Notices
medication therapy and viral load
suppression.
On May 16, 2014 OMB approved the
collection of standardized information
from ten project sites over the three-year
project period and one retrospective
data collection during the first year of
the three-year project period. The
retrospective data collection will
provide information about clients’
baseline characteristics prior to
participation in the model program
which is needed to compare outcomes
before and after program
implementation. On August 17, 2015
OMB approved the conduct of key
informant interviews with program
clinic and pharmacy staff in order to
evaluate the program processes,
administration of a staff communication
questionnaire, and OMB approved the
collection of time and cost data to be
used to estimate the cost of the model
program.
CDC seeks approval to administer a
staff communication questionnaire for
medical providers in order to determine
program activities, will be collected by
program. Qualitative data will be
gathered from program staff through inperson or telephone interviews and
through a questionnaire to program
pharmacy staff and a separate
questionnaire to program clinic staff.
The data collection will allow CDC to
conduct continuous program
performance monitoring which includes
identification of barriers to program
implementation, solutions to those
barriers, and documentation of client
health outcomes. Performance
monitoring will allow the model
program to be adjusted, as needed, in
order to develop a final implementation
model that is self-sustaining and which
can be used to establish similar
collaborations in a variety of clinical
settings. Collection of cost data will
allow for the cost of the program to be
estimated.
There is no cost to participants other
than their time. The total estimated
annualized burden hours are 6,043.
how and if the model program improves
patient outcomes through improved
communication and collaboration
between patients’ clinical providers and
pharmacists. The staff communication
questionnaire for medical providers will
be administered twice to program clinic
staff. The staff communication
questionnaire for medical providers is
different from the previously improved
staff communication questionnaire; the
staff communication questionnaire for
medical providers will be administered
to program clinic staff whereas the staff
communication questionnaire will be
administered to program pharmacy staff.
Pharmacy, laboratory, and medical
data will be collected through
abstraction of all participant clients’
pharmacy and medical records.
Pharmacy, laboratory and medical data
are needed to monitor retention in care,
adherence to therapy, viral load
suppression and other health outcomes.
Program specific data, such as the
number of MTM elements completed
per project site and time spent on
ESTIMATED ANNUALIZED BURDEN HOURS
Average
burden per
response
(in hours)
Number of
responses per
respondent
Number of
respondents
Total burden
(in hours)
Type of respondent
Form name
Clinic Data Manager .........................
Pharmacist ........................................
10
10
3
3
30/60
30/60
15
15
10
100
5/60
83
10
10
10
60
100
400
400
2
1
30/60
30/60
30/60
1,000
2,000
2,000
60
30
40
2
2
30/60
30/60
30
40
Clinic staff .........................................
Pharmacy staff ..................................
Project clinic characteristics form ....
Project pharmacy characteristics
form.
*Patient Demographic Information
form.
*Initial patient information form ........
Quarterly patient information form ...
Pharmacy record abstraction form ...
Interviewer data collection worksheet.
Staff communication questionnaire ..
Staff communication questionnaire
for medical providers.
Clinic cost form ................................
Pharmacy cost form .........................
20
20
2
2
10
10
400
400
Total ...........................................
...........................................................
........................
........................
........................
6,043
Clinic Data Manager .........................
Clinic Data Manager .........................
Clinic Data Manager .........................
Pharmacist ........................................
Key informants ..................................
Project staff (pharmacists) ................
Project staff (medical providers) .......
Leroy A. Richardson,
Chief, Information Collection Review Office,
Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the
Director, Centers for Disease Control and
Prevention.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2015–29274 Filed 11–16–15; 8:45 am]
Board of Scientific Counselors,
National Center for Injury Prevention
and Control: Notice of Charter Renewal
mstockstill on DSK4VPTVN1PROD with NOTICES
BILLING CODE 4163–18–P
Centers for Disease Control and
Prevention
This gives notice under the Federal
Advisory Committee Act (Pub. L. 92–
463) of October 6, 1972, that the Board
of Scientific Counselors, National
Center for Injury Prevention and
Control, Centers for Disease Control and
Prevention (CDC), Department of Health
VerDate Sep<11>2014
18:14 Nov 16, 2015
Jkt 238001
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
and Human Services (HHS), has been
renewed for a 2-year period through
November 5, 2017.
For information, contact Gwendolyn
Cattledge, Ph.D., Designated Federal
Officer, Board of Scientific Counselors,
National Center for Injury Prevention
and Control, CDC, HHS, 1600 Clifton
Road NE., M/S F63, Atlanta, Georgia
30329–4027, Telephone 770/488–4655.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
E:\FR\FM\17NON1.SGM
17NON1
71808
Federal Register / Vol. 80, No. 221 / Tuesday, November 17, 2015 / Notices
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2015–29257 Filed 11–16–15; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
mstockstill on DSK4VPTVN1PROD with NOTICES
Statement of Organization, Functions,
and Delegations of Authority
Part C (Centers for Disease Control
and Prevention) of the Statement of
Organization, Functions, and
Delegations of Authority of the
Department of Health and Human
Services (45 FR 67772–76, dated
October 14, 1980, and corrected at 45 FR
69296, October 20, 1980, as amended
most recently at 80 FR 58479–58485,
dated September 29, 2015) is amended
to reflect the reorganization of the
National Center for Immunization and
Respiratory Diseases, and the Office of
Infectious Diseases, Centers for Disease
Control and Prevention.
Section C–B, Organization and
Functions, is hereby amended as
follows:
Delete in its entirety the title and
function statements for the Influenza
Coordination Unit (CVA4).
Delete in its entirety the title and
function statements for the National
Center for Immunization and
Respiratory Diseases (CVG) and insert
the following:
National Center for Immunization
and Respiratory Diseases (CVG). The
National Center for Immunization and
Respiratory Diseases (NCIRD) prevents
disease, disability, and death through
immunization and by control of
respiratory and related diseases. In
carrying out its mission, NCIRD: (1)
Provides leadership, expertise, and
service in laboratory and
epidemiological sciences, and in
immunization program delivery; (2)
conducts applied research on disease
prevention and control; (3) translates
research findings into public health
policies and practices; (4) provides
diagnostic and reference laboratory
services to relevant partners; (5)
conducts surveillance and research to
determine disease distribution,
determinants, and burden nationally
and internationally; (6) responds to
disease outbreaks domestically and
abroad; (7) ensures that public health
VerDate Sep<11>2014
18:14 Nov 16, 2015
Jkt 238001
decisions are made objectively and
based upon the highest quality of
scientific data; (8) provides technical
expertise, education, and training to
domestic and international partners; (9)
provides leadership to internal and
external partners for establishing and
maintaining immunization, and other
prevention and control programs; (10)
develops, implements, and evaluates
domestic and international public
health policies; (11) communicates
information to increase awareness,
knowledge, and understanding of public
health issues domestically and
internationally, and to promote effective
immunization programs; (12) aligns the
national center focus with the overall
strategic goals of CDC; (13) synchronizes
all aspects of CDC’s pandemic influenza
preparedness and response from
strategy through implementation and
evaluation; and (14) implements,
coordinates, and evaluates programs
across NCIRD, Office of Infectious
Diseases (OID), and CDC to optimize
public health impact.
Delete in its entirety the title and
function statements for the Office of
Laboratory Science (CVG14).
After the Office of Science and
Integrated Programs (CVG17) insert the
following:
Influenza Coordination Unit (CVG18).
The mission of the Influenza
Coordination Unit (ICU) is to
synchronize all aspects of CDC’s
pandemic influenza preparedness and
response from strategy through
implementation and evaluation. In
carrying out its mission, the ICU: (1)
Serves as the principal advisor to the
CDC Director on pandemic influenza
preparedness and response activities,
assisting the Director in formulating and
communicating strategic pandemic
initiatives and policies; (2) provides
strategic leadership for CDC in the areas
of pandemic preparedness and
response, including setting priorities
and promoting science, policies, and
programs related to pandemic influenza;
(3) strategically manages a budget and
allocates funds across the agency to
ensure appropriate resources for high
priority areas; and (4) conducts ongoing
evaluation and adjustment of pandemic
preparedness and response activities, in
coordination with the National
Response Framework and other
emergency preparedness guidance, to
ensure optimal public health
effectiveness and efficient use of human
and fiscal resources by developing and
leading an exercise program for the
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
Agency, in collaboration with HHS and
other partners.
James Seligman,
Acting Chief Operating Officer, Centers for
Disease Control and Prevention.
[FR Doc. 2015–29282 Filed 11–16–15; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Board of Scientific Counselors, Office
of Infectious Diseases (BSC, OID)
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC),
announces the following meeting of the
aforementioned committee:
Time and Date:
8:30 a.m.–5:00 p.m., EST, December 9, 2015
8:00 a.m.–12:00 p.m., EST, December 10,
2015
Place: CDC, Global Communications Center,
1600 Clifton Road, NE., Building 19,
Auditorium B3, Atlanta, Georgia 30333.
Status: The meeting is open to the public,
limited only by the space available.
Purpose: The BSC, OID, provides advice
and guidance to the Secretary, Department of
Health and Human Services; the Director,
CDC; the Director, OID; and the Directors of
the National Center for Immunization and
Respiratory Diseases, the National Center for
Emerging and Zoonotic Infectious Diseases,
and the National Center for HIV/AIDS, Viral
Hepatitis, STD, and TB Prevention, CDC, in
the following areas: Strategies, goals, and
priorities for programs; research within the
national centers; and overall strategic
direction and focus of OID and the national
centers.
Matters for Discussion: The meeting will
include reports from the Board’s Food Safety
Modernization Act Surveillance Working
Group and Infectious Disease Laboratory
Working Group; brief updates on selected
activities of CDC’s infectious disease national
centers; and updates and focused discussions
on prevention of Legionella disease and
efforts to better understand and address
environmental factors contributing to
infectious disease outbreaks.
Agenda items are subject to change as
priorities dictate.
Contact Person for More Information:
Robin Moseley, M.A.T., Designated Federal
Officer, OID, CDC, 1600 Clifton Road NE.,
Mailstop D10, Atlanta, Georgia 30333,
Telephone: (404) 639–4461.
The Director, Management Analysis and
Services Office has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both the Centers for Disease Control and
E:\FR\FM\17NON1.SGM
17NON1
]]>Agencies
[Federal Register Volume 80, Number 221 (Tuesday, November 17, 2015)]
[Notices]
[Pages 71807-71808]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-29257]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Board of Scientific Counselors, National Center for Injury
Prevention and Control: Notice of Charter Renewal
This gives notice under the Federal Advisory Committee Act (Pub. L.
92-463) of October 6, 1972, that the Board of Scientific Counselors,
National Center for Injury Prevention and Control, Centers for Disease
Control and Prevention (CDC), Department of Health and Human Services
(HHS), has been renewed for a 2-year period through November 5, 2017.
For information, contact Gwendolyn Cattledge, Ph.D., Designated
Federal Officer, Board of Scientific Counselors, National Center for
Injury Prevention and Control, CDC, HHS, 1600 Clifton Road NE., M/S
F63, Atlanta, Georgia 30329-4027, Telephone 770/488-4655.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities,
for both the Centers for Disease Control and
[[Page 71808]]
Prevention and the Agency for Toxic Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2015-29257 Filed 11-16-15; 8:45 am]
BILLING CODE 4163-18-P
